Navigation Links
Wistar receives $1.5 million Department of Defense grant to ready prostate drug for clinical use
Date:9/12/2013

To prepare a potential new prostate cancer drug, called Gamitrinib, for trial in humans, The Wistar Institute has received a $1.5 million grant from the US Department of Defense's Congressionally Directed Medical Research Program.

The three-year grant will cover the costs of developing the data necessary to allow the use of Gamitrinib in the clinic. The end goal is to be able to file an Investigational New Drug application with the US Food and Drug Administration, says the drug's inventor and the project's lead investigator, Dario C. Altieri, M.D.

"Years of research have brought us to the point where Gamitrinib is ready for prime time," said Altieri, Wistar's Chief Scientific Officer and director of Wistar's National Cancer Institute-designated Cancer Center. "These funds will help us bridge the gap between a promising discovery and a practical drug for metastatic prostate cancer."

Metastatic prostate cancer remains a devastating disease in need of new therapies, says Altieri. According to the American Cancer Society, prostate cancer will kill about 25,000 Americans each year. "While there have been new prostate cancer drugs in recent years, their success is often measured in prolonging the lives of patients with metastatic disease for weeks or months," Altieri said. "We are interested in adding years to patients' liveswe want cures."

The Altieri laboratory designed Gamitrinib to disable multiple functions of mitochondria in cancer cells, prompting these cells to die. Gamitrinib was also shown to enhance the activity of other targeted cancer therapies in mice. The project began as the Altieri lab explored the role of a molecule called HSP90 in cancers. In particular, a body of evidence suggested that HSP90 accumulated in large amounts in the mitochondria of cancer cells. Mitochondria are organellesstructures within a cellthat help create useful energy for the cell and keep them alive.

While anti-HSP90 drugs exist, and are currently in the clinic, they have limited activity in cancer patients. This may reflect their inability to inhibit HSP90 in mitochondria, which are protected by their own membrane. Using combinatorial chemistry, Altieri and his colleagues created a molecule that would both target HSP90 and accumulate in mitochondria.

"Gamitrinib is, essentially, a two-piece molecule, one part drives it into mitochondria and the other inhibits HSP90," said Altieri. "This became a promising drug concept, one that might apply to multiple forms of advanced cancer, because only cancer cells seem to exploit mitochondrial HSP90 in relevant amounts."

Gamitrinib exploits a critical weakness of cancer cells. While mitochondria control energy production, they also control the inherent self-destruct mechanism within cells, a process called programmed cell death or apoptosis. It is a mechanism that is relevant to many forms of metastatic cancer, and Altieri believes that, in time, the drug will be used to treat many cancers in addition to prostate cancer. Over years of study, the Altieri laboratory has demonstrated how Gamitrinib can prime cancer cell mitochondria for destruction in cell cultures and animal models for many advanced forms of cancer.

The Department of Defense grant will enable the Altieri laboratory to make the final leap between laboratory science and trials in human subjects. The funds will allow Wistar to contract with third-party research organizations to conduct the formulation, toxicology, and pharmacology studies to demonstrate the drug's effectiveness and safety in anticipation of human trials. The funds will also support the development of a suitable biomarkera biological signature that could be measured in patients to demonstrate the effectiveness of Gamitrinib-based therapy.

"In our studies we have shown the mechanism by which Gamitrinib works and potential drug combinations that will kill metastatic prostate cancer cells more effectively," Altieri said. "We are very excited and appreciative that the Congressionally Directed Medical Research Program has chosen our project for funding."

"We have cured a lot of mice, but now we hope to provide new therapeutic options to patients with advanced prostate cancer" Altieri said.


'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3934
The Wistar Institute
Source:Eurekalert

Related biology news :

1. Wistar scientists decipher structure of NatA, an enzyme complex that modifies most human proteins
2. High folate gestational and post-weaning diets in Wistar rat offspring
3. It takes two to tangle: Wistar scientists further unravel telomere biology
4. UCSF receives $4.5M to study value of gene sequencing in newborns
5. Wayne State receives grant to reduce emissions of toxins by power plants into Great Lakes
6. International Rett Syndrome Foundation chief science officer receives prestigious military awards
7. SmartMove, Inc. receives $200,000 grant from the Colorado Office of Economic Development and International Trade
8. Wayne State receives NSF grant to develop plan for field-based water research center
9. VCU receives NIH grant to examine the biology of allergic disease
10. Carnegies Chris Field receives Max Planck Research Prize
11. Penn receives prestigious national award for breakthrough in gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology: